Evaluation of the Efficacy and Safety of Lactobacillus Crispatus M247 (Crispact®) With Vaginal Laser Therapy in Menopausal Women With Atrophic Vulvovaginitis (VVA)

NANot yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Atrophic Vulvovaginitis
Interventions
DEVICE

Monnalisa Touch® Laser Therapy

Monnalisa Touch® laser therapy is a non-ablative fractional CO2 laser applied to the vaginal mucosa to promote tissue regeneration and maintain vaginal health. Participants in this group will receive three sessions of laser therapy, one session every 30 days.

COMBINATION_PRODUCT

Monnalisa Touch® Laser Therapy + Lactobacillus crispatus M247 (Crispact®)

Participants in this group will receive three sessions of Monnalisa Touch® laser therapy, one session every 30 days, along with daily administration of Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU, taken orally for three months.

All Listed Sponsors
collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER